Overview
| Name | Chai-3 · aliases: Chai-3 |
|---|---|
| Full name | No separate expanded name |
| Ambiguous names (not auto-linked) | Chai |
| Family | Not a family entry. Single-model entry, not a family |
| Organization | Chai Discovery |
| Organization type | AI-native biotech |
| Country | United States |
| Model class | Closed molecular design model |
| Domain | Proteins (also: Antibodies) |
| First release | † partly verified Basis: Licence announcement on the company news page, the first public disclosure of Chai-3; no standalone technical report Note: A Business Wire URL id suggests 2026-06-02, which is not a publication date source |
| Other milestones |
|
| Latest update | · product update Basis: Series C announcement calling Chai-3 the latest model (company post) A company funding announcement calls it the latest model; a company event, not a model version Note: The 2026-07-13 collaboration and later pharma deals are not counted as model updates source The most recent sourced event, not a claim that nothing changed since. |
| Status | Product only, no public artifact · No public artifact; only partnerships and company announcements |
| Openness | Code: Closed Weights: Closed Closed; early access for partner pharma companies only |
| Benchmarks reported | 0 counted · none of the 44 |
| Wet-lab validation | None recorded |
| Unverified fields | † first_release |
| As of | 2026-11-16 |
What it does
Closed successor to Chai-2; the company positions it for antibody and multispecific design and harder targets. No technical report, no public benchmark, no public data.
Benchmarks reported
None of the 44 benchmarks. This model is on the zero-pairing list.
How it evaluates itself: Company statements; Pharma partnerships
Other evaluations (outside the 44)
- Company statements (none disclosed) Self-reported: Press releases claim advantages over the predecessor on binding, hard targets, multispecifics and developability; no report or data
- Pharma partnerships (user or partner report) partner: Several licences and collaborations announced; no partner results published
Developers report: Developers report advantages over the predecessor on antibody design and hard targets with roughly double the success rate; no quantified public evidence
Independent evidence: No independent evidence found. No independent evidence found
Training data
Group in Figure 7: Private or licensed data.
| Class | Value | Detail |
|---|---|---|
| a. Public databases | Not disclosed | |
| b. Private or licensed data | Yes | One pharma deal includes a custom model trained on the partner's proprietary data |
| c. Own wet-lab data used for training | Not disclosed | |
| d. Wet lab used only for validation | Not disclosed | The company says wet-lab validation exists; details are not public |
Wet-lab validation
None. The developers report no wet-lab validation.
Background
- Organization: Chai Discovery was founded in San Francisco in 2024 as an AI-native molecular design platform
- Funding: Closed a $400M Series C in 2026-07 at a $3.8B valuation, led by Index Ventures
- Products and partnerships: Licences or collaborations announced with several large pharma companies; financial terms undisclosed
- Related models: Chai-1, Chai-2
Reading notes
- Press-reported success-rate figures conflict and no primary data exists
- Funding and partnership news are not model updates; this record follows that rule
Caveats
- The first-release date rests on the company news page; partly verified
- No public benchmark results; on the zero-pairing list under this round's rules
Sources
- Official page businesswire.com (company blog)
- Official page businesswire.com (company blog)
Corrections
2 corrections
Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-16.